An LSD Pill Just Went 3-for-3 in the Biggest Test of Psychedelic Medicine

Trial two: Voyage (anxiety). Moving into GAD, DT120 delivered a 5.4-point improvement over placebo on the HAM-A anxiety scale at 12 weeks. Primary and key secondary endpoints: all met.

Trial three: Panorama (anxiety). The latest win. Same indication, same dose. The study enrolled 245 participants across three arms (100 µg, 50 µg, and placebo), and the safety profile was clean. No new safety signals, no suicidality concerns, mostly mild and transient side effects.

That consistency matters. One positive trial can be a fluke. Two starts to look real. Three in a row, across two different psychiatric conditions, is the kind of evidence package the FDA takes seriously.

Why Anxiety Is the Right Battlefield

Generalized anxiety disorder affects roughly 3% of U.S. adults at any given time, with about 5.7% experiencing it over their lifetime. Only 43% of those people receive treatment. That's a staggering gap.

The current playbook for GAD isn't terrible, but it's far from great. First-line options include SSRIs, SNRIs, and cognitive behavioral therapy. If those don't work, doctors try a different SSRI or maybe pregabalin. Benzodiazepines (think Xanax) are generally restricted to short-term crisis use because of addiction risk. And if all of that fails? You get referred to a specialist and hope for the best.

The core problem is that many patients never achieve full symptom control. Treatments are slow to kick in, often need to be taken indefinitely, and come with side effects that make people want to quit. A single-dose therapy that produces durable, 12-week-plus benefits would be a fundamentally different proposition. It's the difference between charging your phone every night and having a battery that lasts three months.

The Psychedelic Approval Race

Definium isn't the only company chasing FDA approval for a psychedelic, but it might be running the cleanest race.

The MDMA story has been rocky. Lykos Therapeutics (formerly MAPS) had its MDMA-assisted therapy for PTSD rejected by the FDA in 2024, and that program is still being reworked. Psilocybin is further along: Compass Pathways received a rolling NDA review and a National Priority Voucher for its depression program, with a possible approval decision in late 2026 or early 2027.

But Definium's LSD program now has something neither of those competitors can claim: three positive pivotal trials in the bank. The company says it's assembling the full dataset before sitting down with the FDA to map out the submission strategy, which is a prudent move. You don't rush to file when you're holding a winning hand.

One important wrinkle: even if DT120 gets FDA approval, it won't automatically change LSD's federal controlled-substance status. That requires a separate process through the DEA. The drug would also likely come with a REMS program (Risk Evaluation and Mitigation Strategy), meaning strict rules around how and where it can be prescribed.

What Happens Next

The near-term roadmap looks something like this. Between now and late 2026, Definium will finalize its regulatory strategy and package the data from all three trials. A potential FDA approval by the end of 2027 has been projected, though that's an analyst forecast, not an agency commitment.

The narrative around this company has shifted. It's no longer a question of "does this drug work?" The data have answered that, repeatedly. The questions now are about execution: Can Definium navigate the regulatory path? Can it build a commercial operation for a drug that requires supervised administration? Can it overcome the cultural baggage that comes with putting the letters L-S-D on a prescription label?

Those are real challenges. But they're the kind of challenges you want to have. They're business problems, not science problems. And in biotech, that's a very good place to be.

For millions of people white-knuckling their way through anxiety with treatments that barely move the needle, a single-dose option that works for months isn't just interesting. It's potentially life-changing. Three trials say the science is there. Now comes the hard part: convincing everyone else.

Two Shots a Year. Two Infections Out of 2,180 People.

Gilead's twice-yearly lenacapavir injection produced just 2 HIV infections out of 2,180 people in the PURPOSE 2 trial, crushing daily Truvada by 89%. The science is settled; now comes the hard part.